The typical GHRP-2 researcher is a budget-conscious lifter who wants a strong GH pulse, is willing to accept the cortisol cost for a short cycle, and is usually stacking it with a GHRH like CJC-1295. They are not optimizing for chronic use. They are optimizing for a short, aggressive amplitude window inside a larger training block.
GHRP-2 is a synthetic hexapeptide (6 amino acids) developed in the early 1990s as a second-generation growth hormone secretagogue. It works through the same GHSR-1a ghrelin receptor that Ipamorelin and Hexarelin also bind. The difference is selectivity: GHRP-2 produces a strong GH pulse, but it also nudges cortisol, prolactin, and ACTH in the wrong direction. That cost is the entire reason most modern protocols use Ipamorelin instead.
What GHRP-2 actually is
Sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys. Molecular weight 818 Daltons. It is a synthetic analog of met-enkephalin modified specifically to bind the ghrelin receptor. It was one of the molecules that opened the field of growth hormone secretagogues in the 1990s, alongside GHRP-6 and Hexarelin.
The mechanism in plain English
GHRP-2 binds GHSR-1a on the anterior pituitary. The receptor triggers a calcium-mediated release signal that empties stored GH vesicles into circulation. The GH pulse is large. Larger than Ipamorelin's, in most direct comparisons. But the GHSR-1a receptor also sits on cells that influence the hypothalamic-pituitary-adrenal axis. GHRP-2's downstream signaling is wide enough to hit that adjacent pathway, which is why ACTH and therefore cortisol both rise on dosing. Prolactin rises by a similar mechanism.
Why cortisol matters for the research frame
For a single dose, the cortisol bump is small in absolute terms (peaks at roughly 1.5x baseline and returns to normal within 90 minutes). For a one-week pulse cycle, total cortisol exposure barely shifts. For a 12-week protocol with 2 or 3 doses per day, the integrated cortisol load matters. Chronic cortisol elevation works against the very outcomes the GH pulse is being run for: deeper sleep, faster recovery, lower visceral fat. The math turns against GHRP-2 inside about 3 to 4 weeks of multi-dose-per-day use, which is exactly why long-running protocols moved to Ipamorelin.
Quick reference table
| Spec | Value | Note |
|---|---|---|
| Sequence | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys | Hexapeptide, ~818 Da |
| Standard dose | 100 mcg subq, 2 to 3x daily | Higher doses saturate the receptor |
| GH amplitude | Higher than Ipamorelin | At equimolar comparison |
| Cortisol bump | ~1.3 to 1.6x baseline | Peaks 30 min, resolves 90 min |
| Prolactin bump | Mild but measurable | Larger in some individuals |
| Cycle window | 4 to 6 weeks on, 2 weeks off | Shorter than Ipamorelin protocols |
What GHRP-2 researchers track
The same markers a GH-axis researcher tracks generally apply: sleep depth, IGF-1 on a quarterly blood panel, fasting glucose, body composition over 12 weeks. On GHRP-2 specifically, AM cortisol is the extra marker worth pulling at week 2 and week 4 to confirm the cortisol cost is staying inside a tolerable band. Prolactin can be checked if symptoms (low libido, mood drop) suggest the rise is being felt.
When GHRP-2 still makes sense
Three scenarios. First, short 2 to 4 week amplitude windows where a researcher wants the biggest possible GH pulse and is willing to accept the cortisol cost across a short window. Second, cost-constrained protocols where Ipamorelin is out of budget per dose. Third, researchers who track and respond to the cortisol cost specifically (adaptogens, sleep hygiene, stress management on dosing days) and feel the larger pulse is worth the management overhead.
Compared to Ipamorelin
Larger pulse, dirtier signaling. GHRP-2 wins on raw GH amplitude. Ipamorelin wins on signal cleanliness. For protocols that run longer than 4 weeks at multi-dose-per-day frequency, the cleanliness wins by a wide margin and the field consensus reflects that. For short, aggressive amplitude work, GHRP-2 still has a niche.
External authority and source reading
The Bowers laboratory at Tulane University published the foundational GHRP work in the 1980s and 1990s. The cortisol and prolactin profile of GHRP-2 versus Ipamorelin is documented in Raun et al. (European Journal of Endocrinology) and subsequent reviews in JCEM. The molecule's clinical history runs through Kaken Pharmaceutical's testing programs in Japan and various US Phase 1 and 2 studies that did not proceed to approval.
Compliance frame
GHRP-2 is not FDA-approved. It is sold in the US as research-use-only material for in-vitro and laboratory study. Aion ships GHRP-2 with research-grade labeling and a third-party COA. Any decision about your own use is a conversation for a qualified clinician familiar with peptide research.
Bottom line
GHRP-2 pulses GH harder than its newer cousin and pays for it with a cortisol bump that gets worse the longer you run it. For short amplitude windows it still earns a slot; for anything more than 4 weeks at multi-dose-per-day, the modern field has moved to Ipamorelin and there is a good reason it did.